Published in Neurobiol Dis on January 03, 2007
Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry (2009) 1.51
The vacuolar ATPase is required for physiological as well as pathological activation of the Notch receptor. Development (2010) 1.36
The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci (2012) 1.11
Amyloid precursor protein is trafficked and secreted via synaptic vesicles. PLoS One (2011) 1.06
Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. Front Physiol (2012) 1.05
Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin. Mol Biol Cell (2007) 0.99
Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ (2013) 0.97
Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease. Front Aging Neurosci (2013) 0.94
Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front Aging Neurosci (2014) 0.94
Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway. Mol Brain (2010) 0.92
Co-localization of the amyloid precursor protein and Notch intracellular domains in nuclear transcription factories. Neurobiol Aging (2008) 0.92
ATP6V0C knockdown in neuroblastoma cells alters autophagy-lysosome pathway function and metabolism of proteins that accumulate in neurodegenerative disease. PLoS One (2014) 0.90
Cathepsin L Mediates the Degradation of Novel APP C-Terminal Fragments. Biochemistry (2015) 0.87
The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid. Mol Brain (2014) 0.85
Extracellular vesicles in Alzheimer's disease: friends or foes? Focus on aβ-vesicle interaction. Int J Mol Sci (2015) 0.85
Turnover of amyloid precursor protein family members determines their nuclear signaling capability. PLoS One (2013) 0.84
APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression. Front Aging Neurosci (2015) 0.83
Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology. Acta Neuropathol (2016) 0.82
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis. Eur J Med Chem (2014) 0.82
Arf6 controls beta-amyloid production by regulating macropinocytosis of the Amyloid Precursor Protein to lysosomes. Mol Brain (2015) 0.80
Nicastrin is required for APP but not Notch processing, while Aph-1 is dispensable for processing of both APP and Notch. J Neurochem (2015) 0.77
The Endosome-associated Deubiquitinating Enzyme USP8 Regulates BACE1 Enzyme Ubiquitination and Degradation. J Biol Chem (2016) 0.76
Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca(2+)-Handling Deficits in Alzheimer's Disease Models. NPJ Aging Mech Dis (2016) 0.75
Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases. Int Neurourol J (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24
Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology (2012) 2.87
TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature (2006) 2.56
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science (2009) 2.35
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem (2010) 2.21
Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol (2004) 2.15
CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature (2013) 2.08
MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis (2008) 1.89
Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med (2011) 1.87
Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet (2010) 1.83
Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol (2006) 1.68
Nuclear tau, a key player in neuronal DNA protection. J Biol Chem (2010) 1.47
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem (2003) 1.40
Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J Biol Chem (2007) 1.35
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A (2007) 1.30
Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol (2007) 1.26
Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab (2002) 1.25
Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J (2010) 1.24
Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization. Biochim Biophys Acta (2003) 1.24
Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther (2009) 1.23
AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol (2010) 1.22
Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta (2005) 1.21
Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics (2008) 1.21
Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc Natl Acad Sci U S A (2003) 1.19
Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci (2008) 1.19
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene (2004) 1.17
Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem (2003) 1.17
Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca2+ regulation of neuronal excitability. Proc Natl Acad Sci U S A (2012) 1.16
p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Sci (2005) 1.15
MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet (2011) 1.11
Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem (2003) 1.10
Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem (2011) 1.10
Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun (2014) 1.09
From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans (2010) 1.08
Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res (2006) 1.07
Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci (2012) 1.06
Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. Front Physiol (2012) 1.05
A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol Dis (2009) 1.04
PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. Psychoneuroendocrinology (2008) 1.04
Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol (2007) 1.04
Brain-endocrine interactions: a microvascular route in the mediobasal hypothalamus. Endocrinology (2009) 1.03
Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis (2005) 1.03
The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J Biol Chem (2006) 1.03
Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol (2002) 1.03
Pin1 allows for differential Tau dephosphorylation in neuronal cells. Mol Cell Neurosci (2006) 1.02
ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J Neurosci Res (2006) 1.01
Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1. Biochim Biophys Acta (2005) 1.01
Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. J Alzheimers Dis (2013) 1.00
Pathological determinants of the transition to clinical dementia in Alzheimer's disease. Exp Aging Res (2002) 1.00
Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis (2011) 1.00